Laurus Investment Counsel Inc. Purchases New Position in Integer Holdings Co. (NYSE:ITGR)

Laurus Investment Counsel Inc. acquired a new position in Integer Holdings Co. (NYSE:ITGR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 40,915 shares of the medical equipment provider's stock, valued at approximately $5,422,000. Integer accounts for approximately 2.8% of Laurus Investment Counsel Inc.'s portfolio, making the stock its 11th largest holding. Laurus Investment Counsel Inc. owned 0.12% of Integer at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Integer by 1.2% during the third quarter. Geode Capital Management LLC now owns 764,528 shares of the medical equipment provider's stock valued at $99,408,000 after buying an additional 9,421 shares during the last quarter. Loomis Sayles & Co. L P boosted its stake in Integer by 3.0% during the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider's stock valued at $69,943,000 after buying an additional 15,446 shares during the last quarter. Congress Asset Management Co. boosted its stake in Integer by 3.9% during the third quarter. Congress Asset Management Co. now owns 488,785 shares of the medical equipment provider's stock valued at $63,542,000 after buying an additional 18,303 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Integer by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 404,029 shares of the medical equipment provider's stock valued at $52,524,000 after buying an additional 4,946 shares during the last quarter. Finally, Lord Abbett & CO. LLC raised its position in Integer by 3.5% during the third quarter. Lord Abbett & CO. LLC now owns 290,120 shares of the medical equipment provider's stock valued at $37,716,000 after purchasing an additional 9,754 shares during the period. Institutional investors own 99.29% of the company's stock.

Integer Stock Up 2.7 %

NYSE ITGR traded up $3.79 during midday trading on Wednesday, hitting $143.19. 75,955 shares of the company traded hands, compared to its average volume of 202,891. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The company has a market cap of $4.80 billion, a PE ratio of 44.19, a price-to-earnings-growth ratio of 1.81 and a beta of 1.13. The company's 50-day simple moving average is $137.91 and its 200-day simple moving average is $130.80. Integer Holdings Co. has a 52 week low of $94.56 and a 52 week high of $146.36.

Wall Street Analyst Weigh In

ITGR has been the topic of a number of recent research reports. Citigroup upped their price objective on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. Truist Financial upped their price objective on Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. KeyCorp upped their price objective on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Piper Sandler restated an "overweight" rating and set a $140.00 price objective (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Finally, Wells Fargo & Company restated an "overweight" rating and set a $160.00 price objective on shares of Integer in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $146.56.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.